Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults

    NEXT STORY
    Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
    PREV STORY
    Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aduro Biotech to Present at Two Upcoming Investor Conferences

    BERKELEY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced ...

    author_avatar
    NASDAQ Market News

    BeiGene to Participate in 25th Annual Credit Suisse Healthcare Conference

    WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (Nasdaq:BGNE), a clinical-stage biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Cempra to Report First Quarter 2016 Financial Results

    CHAPEL HILL, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage ...

    author_avatar
    NASDAQ Market News